TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $162 | $141 | $121 | $108 |
| % Growth | 14.6% | 16.8% | 11.7% | – |
| Cost of Goods Sold | $28 | $19 | $16 | $15 |
| Gross Profit | $134 | $122 | $105 | $93 |
| % Margin | 82.6% | 86.6% | 87.1% | 85.8% |
| R&D Expenses | $41 | $32 | $46 | $24 |
| G&A Expenses | $0 | $56 | $50 | $39 |
| SG&A Expenses | $63 | $56 | $50 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $104 | $87 | $97 | $63 |
| Operating Income | $29 | $35 | $9 | $30 |
| % Margin | 18.2% | 24.7% | 7.1% | 27.7% |
| Other Income/Exp. Net | -$3 | -$4 | -$3 | -$4 |
| Pre-Tax Income | $26 | $31 | $5 | $25 |
| Tax Expense | -$365 | $3 | $0 | $2 |
| Net Income | $391 | $28 | $5 | $23 |
| % Margin | 241.7% | 20% | 4.2% | 21.6% |
| EPS | 2.688 | 0.19 | 0.035 | 0.16 |
| % Growth | 1,314.8% | 450.7% | -78.4% | – |
| EPS Diluted | 2.428 | 0.17 | 0.031 | 0.15 |
| Weighted Avg Shares Out | 145 | 147 | 147 | 145 |
| Weighted Avg Shares Out Dil | 161 | 163 | 163 | 160 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $7 | $7 | $7 | $7 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $33 | $38 | $12 | $33 |
| % Margin | 20.2% | 26.7% | 10.2% | 30.1% |